Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer

NCT00048633 is registered in ClinicalTrials.gov with QLT Inc. as lead sponsor.

NCT NCT00048633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00048633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer
Lead sponsor
QLT Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2001
Completion date
June 30, 2003
Enrollment
30
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms